Sun Pharma share price rallies 62% from March lows; should you buy the stock? Check target prices

By: |
Published: June 12, 2020 12:52 PM

Sun Pharmaceuticals Industries stock has been on a gaining spree since it touched a 52-week low of Rs 315.20 in March this year

Sun Pharmaceuticals, Sun pharma, sun pharma share priceSun Pharmaceuticals rallied over 62 per cent from its March low and hit a 52-week high of 512.55 earlier this week.

Even as Indian share market traded with nearly 1.5 per cent cuts on Friday, taking cues from the global markets, Sun Pharma was among top four BSE Sensex gainers today. Sun Pharma stock gained 1 per cent to hit day’s high of Rs 479 apiece on BSE today. Sun Pharmaceuticals Industries stock has been on a gaining spree since it touched a 52-week low of Rs 315.20 in March this year. It rallied over 62 per cent from its March low and hit a 52-week high of 512.55 earlier this week. Research and brokerage firms are upbeat on the stock and recommend it to buy with an upside of over 30 per cent at a price target of Rs 620. “Company maintains its leadership position in the domestic market and support from ROW markets is healthy. The US market has been steady and improving base riding on speciality,” Centrum Broking said in a report.

The brokerage firm has maintained its buying rating to the stock. Sun Pharma stock will have to jump 31 per cent from its Thursday’s close, to reach the target price of Rs 620 pegged by the Centrum Broking. “We anticipate the speciality basket focus strategy to start paying dividends from FY21E onwards which would add significant delta to earnings going ahead,” it added.

Five Indian firms including Sun Pharmaceuticals, are among the 26 drug makers facing a multi-state lawsuit filed in the US for alleged conspiracy to artificially inflate and manipulate prices, reducing competition for generic drugs sold across the United States. “Previous instances of price-fixing show that fines get significantly discounted, based on a company’s level of cooperation and can range from full immunity for first-to cooperate and significant discounts for second-in,” DART said in its latest report. The brokerage sees 12 per cent upside in the stock with a target price of Rs 530.

However, global research firm Credit Suisse is neutral on the stock with up to 20 per cent downside at a target of Rs 400. “Our neutral rating for Sun Pharma is driven by the slow ramp-up of speciality drugs and weaker-than-expected pace of approvals in the US generic business, which will be further impacted by Halol facility’s OAI classification,” it said in its recent report.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Sensex, Nifty continue to climb up for the fourth day straight; factors that fueled the rally today
2Average spot power price drops 29 pc to Rs 2.35/unit on IEX
3With just 3.5% away from 52-week high, Bharti Airtel stock getting back to its competitive best